サンプル依頼リスト カート
  • English
  • Korean
表紙：創薬アウトソーシングサービスの世界市場：2023年～2030年
市場調査レポート
商品コード
1382551

創薬アウトソーシングサービスの世界市場：2023年～2030年

Global Drug Discovery Outsourcing Services Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
創薬アウトソーシングサービスの世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

創薬アウトソーシングサービスとは、様々な治療領域や疾患に対する新薬の発見・開発を促進するための科学的・技術的サービスの範囲を指します。創薬プロセスには、疾患プロセスに関与するタンパク質や遺伝子などの潜在的な創薬標的を同定し、その治療可能性を検証する標的同定が含まれます。医薬品化学、吸収・分布・代謝・排泄・毒性のADME-TOX試験による体内での薬物の挙動と潜在的な副作用の評価、薬理学的試験による有効性・安全性・薬理学的特性の評価、前臨床開発・製剤開発に続く臨床試験などが含まれます。

市場力学：促進要因と阻害要因

AIを活用した創薬手法の台頭

AIの活用を期待する企業は、断片的なデータだけでなく、全データの全体像を把握する必要があります。そのためには、計算チームと実験チームが協力し、ワークフローを統合し、領域や場所を超えてデータを共有できるような研究インフラが必要となります。AIの助けを借りて得られた結果が再現可能であることを保証するためには、慎重なプロセスと手法の標準化も必要です。

例えば、2023年7月、キッセイ薬品工業株式会社は、AI医薬品「マキア」を発表しました。Iktos社のAI創薬システムMakyaを導入しました。これにより、AI技術を駆使して標的基準に適した新規低分子の迅速な設計が可能となり、創薬開発のスピードアップにつながります。

さらに2023年5月、グーグルクラウドは、バイオテクノロジー会社、製薬会社、公的機関向けに、創薬と精密医療を加速させる2つの新しいAI搭載ライフサイエンスソリューションを発表しました。全世界で利用可能なTarget and Lead Identification Suiteは、研究者がアミノ酸の機能を特定し、タンパク質の構造を予測するのに役立ちます。Multiomics Suiteは、ゲノムデータの発見と解釈を加速し、企業が精密治療を設計するのに役立ちます。

さらに、慢性疾患の増加、生物製剤市場の拡大、研究開発施設の増加といった要因がドラッグデリバリー市場を拡大させており、Al統合やヘルスケアのデジタル化といった最新の技術進歩が市場に新たな機会を生み出しています。

市場力学：阻害要因

世界の創薬アウトソーシング市場の成長を阻害すると予想される主な要因の1つは、医薬品開発コストの高さです。医薬品開発は高額で時間のかかる長期的なプロセスです。創薬のための前臨床試験に関連するコストの高さは最大の課題です。また、医薬品製造に関する厳しい規則や規制、知的財産権、CMOによる規制要件不遵守のリスクなど、その他の要因も予測期間中の市場成長を妨げます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • AIを活用した創薬手法の台頭
      • 慢性疾患の増加
    • 抑制要因
      • 創薬コストの高さ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 サービスタイプ別

  • 医療化学サービス
  • 生物学サービス

第8章 医薬品タイプ別

  • 低分子
  • 大型分子（バイオ医薬品）

第9章 治療領域別

  • がん領域
  • 感染症
  • 呼吸器疾患
  • 循環器
  • 消化器
  • その他

第10章 エンドユーザー別

  • 受託研究機関
  • 製薬・バイオテクノロジー企業
  • 学術機関
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • ThermoFisher Scientific
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Charles River Laboratories International, Inc
  • WuXi AppTec Co., Ltd.,
  • Albany Molecular Research, Inc.,
  • Aragen Life Sciences Ltd
  • Sygnature Discovery,
  • Pharmaron Beijing Co., Ltd.,
  • Domainex Ltd.,
  • Jubilant Biosys Ltd.
  • Evotec

第14章 付録

目次
Product Code: PH7475

Overview

Drug discovery outsourcing services refer to the range of scientific and technological services to facilitate the discovery and development of new drugs for various therapeutic areas or diseases. The drug discovery process includes target identification to identify potential drug targets, such as proteins or genes involved in disease processes, and validate their therapeutic potential. Medicinal chemistry, ADME-TOX studies which are absorption, distribution, metabolism, excretion, and toxicity to assess the behaviour of the drug within the body and its potential adverse effects, pharmacology studies to assess the efficacy, safety and pharmacological properties and preclinical development and formulation development followed by clinical trials.

Market Dynamics: Drivers and Restraints

Rise in the AI-enabled drug discovery methods

Companies hoping to leverage AI need a full view of all their data, not just bits and pieces. This demands a research infrastructure that lets computational and experimental teams collaborate, uniting workflows and sharing data across domains and locations. Careful process and methodology standardization are also needed to ensure that results obtained with the help of AI are repeatable.

For instance, in July 2023, kissei Pharmaceutical Co., Ltd. Introduced Makya, an AI drug discovery system from Iktos. This will enable the rapid design of new small molecules suitable for target criteria using AI technology, leading to an increase in the speed of drug discovery and development.

Moreover, in May 2023, Google Cloud announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. Available worldwide, the Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and interpretation of genomic data, helping companies design precision treatments.

Furthermore, factors like the rise in chronic diseases, expanding biologics market, and increasing research and development facilities are increasing the pharmaceutical drug delivery market, latest technological advancements such as Al integration and healthcare digitization create new opportunities for the market.

Market Dynamics: Restraint

One of the key factors expected to hamper the growth of the global drug discovery outsourcing market is the high cost of drug development. Drug development is an expensive, time-consuming, and long-term process. Higher costs associated with preclinical studies for drug discovery are the biggest challenge. Also, other factors like stringent rules & regulations for drug manufacturing, intellectual property rights, Risk of non-compliance with regulatory requirements by CMO and others factors hamper the market growth during the forecast period.

Segment Analysis

The global drug discovery outsourcing services market is segmented based on service type, drug type, therapeutic areas, end user and region.

The biology services segment from the service type segment accounted for approximately 41.7% of the drug discovery outsourcing services market share

The biology services segment from the service type segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Biological services encompass a range of specialized offerings that involve the study and manipulation of biological systems, such as cells, tissues, and biomolecules, to facilitate the identification and development of potential therapeutic compounds. Biological services play a pivotal role in assessing the interactions between complex potential drug candidates and living organisms at the cellular and molecular levels.

For instance, in January 2023, BenchSci is excited to announce the launch of our latest technology that aims to transform and improve outcomes and timelines for this crucial stage of drug discovery. ASCEND by BenchSci, our revolutionary new AI software platform has the potential to fundamentally change preclinical research. Building on the success of our AI-assisted reagent selection application, we've developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early to move the most promising projects forward faster.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the technological advancements, presence of well-established research infrastructure & key players, and higher investments in drug discovery R&D, acquisitions with key players, rising need for efficiency, quality, and innovation are expected to contribute to market growth.

For instance, in April 2022, Charles River Laboratories International and Valo Health launched Logica, an AI-powered drug solution that translates clients' biological insights into optimized preclinical assets. The solution uses Valo's AI-powered Opal Computational Platform and Charles River's preclinical expertise to provide clients with a single integrated offering, translating targets to candidate nominations. The partnership aims to integrate Charles River's laboratory capabilities with AI-driven molecular design, providing clients with advanced leads and candidates while tying client costs to value generation.

Moreover, in December 2021, Labcorp stated that it had acquired Toxikon Corporation, a contract research company offering nonclinical testing services. The addition of Toxikon to LabCorp drug development enhances the company's strong nonclinical development portfolio and assists in generating a strategic footprint for the company to partner with pharmaceutical and biotechnology clients.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the drug discovery outsourcing services market owing to the high demand for vaccine discovery by various pharmaceutical and biotech companies in the past three years. Drug discovery outsourcing has become a key aspect of developing effective treatments against the virus. For instance, in June 2021, Catalent, Inc. collaborated with Moderna, Inc. for the manufacturing of the Moderna COVID-19 vaccine and potentially other investigational programs in Moderna's pipeline at Catalent's biologics facility in Bloomington, Indiana.

Market Segmentation

By Service Type

  • Medical Chemistry Services
  • Biology Services

By Drug Type

  • Small Molecule
  • Large Molecules (Biopharmaceuticals)

By Therapeutic Areas

  • Oncology
  • Infectious Disease
  • Respiratory Disease
  • Cardiovascular
  • Gastrointestinal
  • Others

By End User

  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Academic Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

major global players in the market include: ThermoFisher Scientific, Charles River Laboratories International Inc., WuXi AppTec Co.Ltd., Albany Molecular Research, Inc., Aragen Life Sciences Ltd, Sygnature Discovery, Pharmaron Beijing Co. Ltd, Domainex Ltd., Jubilant Biosys Ltd., Evotec and among others.

Key Developments

  • In November 2022, Sanofi and Insilico Medicine, a clinical-stage biotechnology company, inked a USD 1200 million Drug Development Deal. The agreement will see Sanofi use Insilico's AI platform, Pharma.AI, to advance drug development in up to six new targets.
  • In October 2022, Amphista Therapeutics, a biotechnology company focusing on drug discovery projects that use targeted protein degradation (TPD), collaborated with Domainex, a medicines research service partner, as a partner to provide integrated drug discovery services for its research programs. Amphista will benefit from the expertise in protein production, assay biology, and medicinal chemistry of Domainex.

Why Purchase the Report?

  • To visualize the global drug discovery outsourcing services market segmentation based on service type, drug type, therapeutic areas, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analysing trends and co-development.
  • Excel data sheet with numerous data points of drug discovery outsourcing services market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global drug discovery outsourcing services market report would provide approximately 61 tables, 58 figures and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Service Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by Therapeutic Areas
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the AI-enabled drug discovery methods
      • 4.1.1.2. Rise in the prevalence of chronic diseases
    • 4.1.2. Restraints
      • 4.1.2.1. High cost of drug discovery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Service Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 7.1.2. Market Attractiveness Index, By Service Type
  • 7.2. Medical Chemistry Services*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Biology Services

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Small Molecule *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Large Molecules (Biopharmaceuticals)

9. By Therapeutic Areas

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 9.1.2. Market Attractiveness Index, By Therapeutic Areas
  • 9.2. Oncology *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Infectious Disease
  • 9.4. Respiratory Disease
  • 9.5. Cardiovascular
  • 9.6. Gastrointestinal
  • 9.7. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Contract Research Organizations*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Pharmaceutical & Biotechnology Companies
  • 10.4. Academic Institutes
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. ThermoFisher Scientific*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Charles River Laboratories International, Inc
  • 13.3. WuXi AppTec Co., Ltd.,
  • 13.4. Albany Molecular Research, Inc.,
  • 13.5. Aragen Life Sciences Ltd
  • 13.6. Sygnature Discovery,
  • 13.7. Pharmaron Beijing Co., Ltd.,
  • 13.8. Domainex Ltd.,
  • 13.9. Jubilant Biosys Ltd.
  • 13.10. Evotec

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us